---
layout: post
title: "Prospective Grant of Exclusive Patent License: Radiotherapeutics for Nasopharyngeal Cancer"
date: 2026-02-05 19:01:09 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-22476
original_published: 2022-10-17 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of Exclusive Patent License: Radiotherapeutics for Nasopharyngeal Cancer

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 17, 2022 00:00 UTC
**Document Number:** 2022-22476

## Summary

The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Molecular Targeting Technologies, Inc. (MTTI); a Delaware corporation, with its principle place of business in West Chester, Pennsylvania, to practice the inventions embodied in the issued patents and patent applications listed in the Supplementary Information section of this notice.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/17/2022-22476/prospective-grant-of-exclusive-patent-license-radiotherapeutics-for-nasopharyngeal-cancer)
- API: https://www.federalregister.gov/api/v1/documents/2022-22476

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
